(Q48161067)

English

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

0 references

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1

object named as

Ethan Basch

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

7

object named as

Karim Fizazi

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

Charles S Cleeland

17

object named as

Charles Cleeland

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

author name string

Karen Autio

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Charles J Ryan

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Peter Mulders

4

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Neal Shore

5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Thian Kheoh

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Christopher J Logothetis

8

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Dana Rathkopf

9

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Matthew R Smith

10

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Paul N Mainwaring

11

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Yanni Hao

12

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Thomas Griffin

13

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Susan Li

14

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Michael L Meyers

15

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Arturo Molina

16

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

publication date

25 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

14

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

12

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

1193-1199

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Castration-resistant prostate cancer: locking up the molecular escape routes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone in metastatic prostate cancer without previous chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging novel therapies for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of skeletal complications on patients' quality of life, mobility, and functional independence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The physical burden of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of patient-reported questionnaire data: another step toward consensus.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pain in castration-resistant prostate cancer with bone metastases: a qualitative study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Toward patient-centered drug development in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970424-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70424-8

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24075621

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48161067&oldid=2188221311"